Pharmaceutical manufacturer Granules India reported a 55 per cent rise in sales at Rs 317 crore for the last quarter (Q4) of the financial year 2013-14, as against Rs 204.51 crore in the same period last year.
Ebitda grew 87 per cent to Rs 163 crore. The growth in Q4 was led by commercialisation of pharmaceutical formulation intermediaries (PFI)and finished dosage expansion at the Gagillapur facility.
"Over the long-term, we will add value by offering finished dosages from select APIs in the same portfolio. We will continue to strengthen our model and build systems that are sustainable as we continue to scale-up, said Krishna Prasad, managing director of Granules India in a release.
